Nathalie Fuentes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nathalie Fuentes has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Patricia Silveyra
Indiana University
3 shared publications Stanley C. Kwok
Dosage Form Design and Development, BioPharmaceutical Development, R&D, AstraZeneca, Gaithersburg, USA
3 shared publicationsAnnette M. Medina
Dosage Form Design and Development, BioPharmaceutical Development, R&D, AstraZeneca, Gaithersburg, USA
2 shared publications- Giorgia De Paoli
School of Health Sciences, University of Dundee, Dundee, United Kingdom
2 shared publications - Léa Sorret
Drug Product Services, Lonza AG, Hochbergerstrasse 60G, 4057 Basel, Switzerland
2 shared publications - Mattias Paulsson
Department of Women's and Children's Health Uppsala University Uppsala Sweden
2 shared publications
Latest Publications
- Open Access
- 19 March 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (5) , 104253
Multidisciplinary exploratory survey: Initial insights into biologic drug handling and regulatory perspectives among healthcare professionals
- 19 March 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (5) , 104253
Open AccessMultidisciplinary exploratory survey: Initial insights into biologic drug handling and regulatory perspectives among healthcare professionals
- Open Access
- 16 May 2025
- Published by Springer Nature in Pharmaceutical Research
- Vol. 42 (6) , 961-972
Assessment of the Effects of Ionizing Radiation on Biologic Drugs: mAb Product Quality and Risk Evaluation for Global Shipping Logistics
Purpose It is critical to ensure that drug product quality is not negatively impacted after transportation and shipping so that the product remains safe and effective. The traditional shipping validation and product quality assessments focus on factors such as temperature, vibration, shock, agitation, light exposure, and potential contamination. At the same time, due to the complexity of biologics modalities including cell therapy products, the increasing prevalence of non-intrusive inspection (NII) technologies employing ionizing radiation such as X-ray and Gamma rays at security screening at border points has prompted an evaluation of their impact on biologics. Methods In this study, the effect of X-ray radiation on monoclonal antibody (mAb)-related biologic drug substance and drug products was investigated by subjecting them to worst-case scenario radiation levels, approximately 200 times higher than the recommended dose, within commonly deployed shipping packaging and primary container. Subsequently, product quality attributes, including visible particles, sub-visible particles, purity, and charge variants, were assessed. Results The results revealed no significant changes in the exposed samples compared to controls, indicating that the mAb-related biologics maintained their product quality despite exposure to heightened X-ray radiation. Conclusions These findings provide valuable assurance regarding the stability and safety of mAb-related biologics when subjected to X-ray radiation during transportation and security screenings. Our goal is that this work will stimulate further discussion and guidance from drug sponsors and health authorities to evaluate ionizing radiation impact on current biologics and others new modalities to ensure drug and patient safety.
- 16 May 2025
- Published by Springer Nature in Pharmaceutical Research
- Vol. 42 (6) , 961-972
Open AccessAssessment of the Effects of Ionizing Radiation on Biologic Drugs: mAb Product Quality and Risk Evaluation for Global Shipping Logistics
Purpose It is critical to ensure that drug product quality is not negatively impacted after transportation and shipping so that the product remains safe and effective. The traditional shipping validation and product quality assessments focus on factors such as temperature, vibration, shock, agitation, light exposure, and potential contamination. At the same time, due to the complexity of biologics modalities including cell therapy products, the increasing prevalence of non-intrusive inspection (NII) technologies employing ionizing radiation such as X-ray and Gamma rays at security screening at border points has prompted an evaluation of their impact on biologics. Methods In this study, the effect of X-ray radiation on monoclonal antibody (mAb)-related biologic drug substance and drug products was investigated by subjecting them to worst-case scenario radiation levels, approximately 200 times higher than the recommended dose, within commonly deployed shipping packaging and primary container. Subsequently, product quality attributes, including visible particles, sub-visible particles, purity, and charge variants, were assessed. Results The results revealed no significant changes in the exposed samples compared to controls, indicating that the mAb-related biologics maintained their product quality despite exposure to heightened X-ray radiation. Conclusions These findings provide valuable assurance regarding the stability and safety of mAb-related biologics when subjected to X-ray radiation during transportation and security screenings. Our goal is that this work will stimulate further discussion and guidance from drug sponsors and health authorities to evaluate ionizing radiation impact on current biologics and others new modalities to ensure drug and patient safety.
- Open Access
- 28 November 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (1) , 108028
Targeting cytoskeletal biomechanics to modulate airway smooth muscle contraction in asthma
- 28 November 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (1) , 108028
Open AccessTargeting cytoskeletal biomechanics to modulate airway smooth muscle contraction in asthma
- Open Access
- 22 August 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (2) , 681-689
Drug product development and case studies for patient centric pediatric protein-based therapeutics
- 22 August 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (2) , 681-689
Open AccessDrug product development and case studies for patient centric pediatric protein-based therapeutics
- Open Access
- 27 May 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (8) , 2055-2064
Impact of Post Manufacturing Handling of Protein-Based Biologic Drugs on Product Quality and User Centricity
- 27 May 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (8) , 2055-2064
Open AccessImpact of Post Manufacturing Handling of Protein-Based Biologic Drugs on Product Quality and User Centricity
- 3 June 2021
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 246 (19) , 2098-2110
Role of sex hormones in lung cancer
Lung cancer represents the world’s leading cause of cancer deaths. Sex differences in the incidence and mortality rates for various types of lung cancers have been identified, but the biological and endocrine mechanisms implicated in these disparities have not yet been determined. While some cancers such as lung adenocarcinoma are more commonly found among women than men, others like squamous cell carcinoma display the opposite pattern or show no sex differences. Associations of tobacco product use rates, susceptibility to carcinogens, occupational exposures, and indoor and outdoor air pollution have also been linked to differential rates of lung cancer occurrence and mortality between sexes. While roles for sex hormones in other types of cancers affecting women or men have been identified and described, little is known about the influence of sex hormones in lung cancer. One potential mechanism identified to date is the synergism between estrogen and some tobacco compounds, and oncogene mutations, in inducing the expression of metabolic enzymes, leading to enhanced formation of reactive oxygen species and DNA adducts, and subsequent lung carcinogenesis. In this review, we present the literature available regarding sex differences in cancer rates, associations of male and female sex hormones with lung cancer, the influence of exogenous hormone therapy in women, and potential mechanisms mediated by male and female sex hormone receptors in lung carcinogenesis. The influence of biological sex on lung disease has recently been established, thus new research incorporating this variable will shed light on the mechanisms behind the observed disparities in lung cancer rates, and potentially lead to the development of new therapeutics to treat this devastating disease.
- 3 June 2021
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 246 (19) , 2098-2110
Role of sex hormones in lung cancer
Lung cancer represents the world’s leading cause of cancer deaths. Sex differences in the incidence and mortality rates for various types of lung cancers have been identified, but the biological and endocrine mechanisms implicated in these disparities have not yet been determined. While some cancers such as lung adenocarcinoma are more commonly found among women than men, others like squamous cell carcinoma display the opposite pattern or show no sex differences. Associations of tobacco product use rates, susceptibility to carcinogens, occupational exposures, and indoor and outdoor air pollution have also been linked to differential rates of lung cancer occurrence and mortality between sexes. While roles for sex hormones in other types of cancers affecting women or men have been identified and described, little is known about the influence of sex hormones in lung cancer. One potential mechanism identified to date is the synergism between estrogen and some tobacco compounds, and oncogene mutations, in inducing the expression of metabolic enzymes, leading to enhanced formation of reactive oxygen species and DNA adducts, and subsequent lung carcinogenesis. In this review, we present the literature available regarding sex differences in cancer rates, associations of male and female sex hormones with lung cancer, the influence of exogenous hormone therapy in women, and potential mechanisms mediated by male and female sex hormone receptors in lung carcinogenesis. The influence of biological sex on lung disease has recently been established, thus new research incorporating this variable will shed light on the mechanisms behind the observed disparities in lung cancer rates, and potentially lead to the development of new therapeutics to treat this devastating disease.
- 11 November 2020
- Published by Springer Nature in Journal of Perinatology
- Vol. 41 (3) , 551-561
Tracheal aspirate transcriptomic and miRNA signatures of extreme premature birth with bronchopulmonary dysplasia
Objective Extreme preterm infants are a growing population in neonatal intensive care units who carry a high mortality and morbidity. Multiple factors play a role in preterm birth, resulting in major impact on organogenesis leading to complications including bronchopulmonary dysplasia (BPD). The goal of this study was to identify biomarker signatures associated with prematurity and BPD. Study design We analyzed miRNA and mRNA profiles in tracheal aspirates (TAs) from 55 infants receiving invasive mechanical ventilation. Twenty-eight infants were extremely preterm and diagnosed with BPD, and 27 were term babies receiving invasive mechanical ventilation for elective procedures. Result We found 22 miRNAs and 33 genes differentially expressed (FDR < 0.05) in TAs of extreme preterm infants with BPD vs. term babies without BPD. Pathway analysis showed associations with inflammatory response, cellular growth/proliferation, and tissue development. Conclusions Specific mRNA-miRNA signatures in TAs may serve as biomarkers for BPD pathogenesis, a consequence of extreme prematurity.
- 11 November 2020
- Published by Springer Nature in Journal of Perinatology
- Vol. 41 (3) , 551-561
Tracheal aspirate transcriptomic and miRNA signatures of extreme premature birth with bronchopulmonary dysplasia
Objective Extreme preterm infants are a growing population in neonatal intensive care units who carry a high mortality and morbidity. Multiple factors play a role in preterm birth, resulting in major impact on organogenesis leading to complications including bronchopulmonary dysplasia (BPD). The goal of this study was to identify biomarker signatures associated with prematurity and BPD. Study design We analyzed miRNA and mRNA profiles in tracheal aspirates (TAs) from 55 infants receiving invasive mechanical ventilation. Twenty-eight infants were extremely preterm and diagnosed with BPD, and 27 were term babies receiving invasive mechanical ventilation for elective procedures. Result We found 22 miRNAs and 33 genes differentially expressed (FDR < 0.05) in TAs of extreme preterm infants with BPD vs. term babies without BPD. Pathway analysis showed associations with inflammatory response, cellular growth/proliferation, and tissue development. Conclusions Specific mRNA-miRNA signatures in TAs may serve as biomarkers for BPD pathogenesis, a consequence of extreme prematurity.
- 1 May 2019
- Published by Elsevier in Respiratory Medicine
- Vol. 151, 133-138
The role of microRNAs in chronic pseudomonas lung infection in Cystic fibrosis
- 1 May 2019
- Published by Elsevier in Respiratory Medicine
- Vol. 151, 133-138
The role of microRNAs in chronic pseudomonas lung infection in Cystic fibrosis